Press release
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020
CANTON, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the
About this update from Organogenesis Holdings Inc.
[{"type":"text","content":"CANTON, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary revenue results for the three months ended June 30, 2020. \n Second Quarter 2020 Preliminary Revenue Summary: Net revenue of between $68.0 million and $68.6 million for the three months ended June 30, 2020, up 5% to 6% compared to net revenue of $64.9 million for the three months ended June 30, 2019. Net revenue is based upon: Net revenue from Advanced Wound Care products of between $59.7 million and $60.1 million, up 8% to 9% year-over-year.Net revenue from Surgical & Sports Medicine products of between $8.3 million and $8.5 million, down 13% to 15% year-over-year. Net revenue from the sale of PuraPly products of between $27.7 million and $28.1 million for the three months ended June 30, 2020, down 5% to 7% year-over-year. Second Quarter 2020 Earnings Conference Call: Financial results for the second fiscal quarter of 2020 will be reported after the market closes on Monday, August 10, 2020. Management will host a conference call at 5:00 p.m. Eastern Time on August 10 to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 4153175. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com. For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 4153175. The webcast will be archived at investors.organogenesis.com. Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predic...